Biotech Values

[Superfly15]

After looking more deeply at peri's clinical data, I didn't need AF's market cap rule to tell me that X-PECT's chance of succeeding wasn't going to be good (though I did think there would at least be an efficacious sub-group).

As did I. Again, I said it is something for NEW biotech investors to keep an eye on. Not everybody knows how to read in-depth pharma data when starting...myself included. 3 years going and I still have much to learn.